var data={"title":"Nadroparin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nadroparin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6617?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nadroparin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nadroparin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199025\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fraxiparine;</li>\n      <li>Fraxiparine Forte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199059\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Low Molecular Weight Heparin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199028\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose expressed as anti-Xa international units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndromes (unstable angina and NSTEMI [non-Q-wave myocardial infarction] in conjunction with aspirin):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: IV: 86 units/kg bolus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: SubQ: 86 units/kg every 12 hours (usual treatment duration: 6 days); plasma anti-Xa levels should be &lt;1.2 anti-Xa units/mL 3 to 4 hours postinjection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anticoagulation during hemodialysis:</b> Single dose of ~65 units/kg into arterial line at start of each dialysis session; may give additional dose if session lasts longer than 4 hours; adjust dose during subsequent dialysis sessions to plasma anti-Xa levels of 0.5 to 1 anti-Xa units/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients at risk of hemorrhage:</i> Single dose of ~32.5 units/kg into arterial line at start of each dialysis session; may give additional smaller dose if session lasts longer than 4 hours; adjust dose during subsequent dialysis sessions to plasma anti-Xa levels of 0.2 to 0.4 anti-Xa units/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT treatment:</b> SubQ: 171 units/kg once daily (maximum dose: 17,100 units/day); expected plasma anti-Xa levels are 1.2 to 1.8 anti-Xa units/mL 3 to 4 hours postinjection. <b>Note:</b> Patients at an increased risk of bleeding should receive a dose of 86 units/kg every 12 hours with expected plasma anti-Xa levels of 0.5 to 1.1 anti-Xa units/mL 3 to 4 hours postinjection. In patients with VTE and <i>without</i> cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) (Kearon 2012; Kearon 2016). In patients transitioning to warfarin, start warfarin on the first or second treatment day and continue nadroparin until INR is &ge;2 for at least 24 hours (usually 5 to 7 days) (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity:</i> Use actual body weight to calculate dose; a fixed upper dose limit is not recommended; however, increased monitoring may be warranted (see monitoring parameters) (Nutescu 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy: </i>Based on the cause of VTE, risk of recurrence and risk of bleeding. Refer to guidelines for specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thromboprophylaxis:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>General surgery:</i> Initial: 2,850 units administered 2 to 4 hours preoperatively; Maintenance: SubQ: 2,850 units once daily. Continue therapy for at least 7 days and until ambulant or no longer at DVT risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High-risk </i>\n      <i>medical patients (respiratory failure and/or respiratory infection and/or cardiac failure):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;70 kg: 3,800 units once daily during the risk period of thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;70 kg: 5,700 units once daily during the risk period of thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hip replacement surgery:</i> Initial: 38 units/kg 12 hours before and after surgery, followed by 38 units/kg once daily up to and including postoperative day 3; postoperative day 4 begin 57 units/kg once daily. Continue therapy for at least 10 days and until ambulant or no longer at DVT risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity:</i> <b>Note:</b> In morbidly obese patients (BMI &ge;40 kg/m<sup>2</sup>), increasing the prophylactic dose by 30% may be appropriate for some indications (Nutescu 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062283\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution (increased risk of bleeding in the elderly). Close monitoring necessary, especially in patients with low body weight (ie, &lt;45 kg) or predisposed to renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thromboprophylaxis in high-risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure), immobilized due to acute illness or in ICU: Consider dose reduction to 2,850 units once daily during the risk period of thromboembolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199029\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 to &lt;50 mL/minute: Decrease dose by 25% to 33%. Some have suggested that no dose adjustment is needed when used for prophylaxis; one small clinical trial found no change in peak anti-Xa activity after 5 days of nadroparin at prophylactic doses (Atiq 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: Reduce dose by 25% to 33%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13219378\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27749650\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications). The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (Gould 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076317\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, as calcium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fraxiparine:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9500 anti-Xa units/mL (0.3 mL, 0.4 mL) [ungraduated prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9500 anti-Xa units/mL (0.6 mL, 1 mL) [graduated prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fraxiparine Forte: 19,000 anti-Xa units/mL (0.6 mL, 0.8 mL, 1 mL) [graduated prefilled syringe]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234097\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199008\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Administer by SubQ injection into anterolateral abdominal wall with subsequent doses to be administered alternately on right and left side of abdominal wall. The thigh may also be used as an alternative site. Do <b>not</b> administer intramuscularly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May be administered IV only as initial bolus dose for acute coronary syndromes (unstable angina and NSTEMI [ie, non-Q-wave myocardial infarction]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Inject into arterial line at start of dialysis session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199007\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fraxiparine:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute coronary syndromes:</b> Treatment of unstable angina and non-ST-elevation myocardial infarction (NSTEMI) myocardial infarction (ie, non-Q wave MI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anticoagulation during hemodialysis: </b>Prevention of clotting during hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Deep vein thrombosis: </b>Treatment of deep vein thrombosis (DVT). <b>Note:</b> In patients with venous thromboembolism (VTE) (ie, DVT or PE) and <i>without</i> cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin). In patients with venous thromboembolism (VTE) (ie, DVT or PE) <b>and</b> cancer, ACCP recommends LMWH over oral anticoagulants for initial and long-term treatment (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thromboprophylaxis:</b> Prophylaxis of thromboembolic disorders (particularly DVT and pulmonary embolism [PE]) in general and orthopedic surgery, high-risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) immobilized due to acute illness or hospitalized in ICU</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fraxiparine Forte: </b>Treatment of deep vein thrombosis (DVT)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199064\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198996\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. As with all anticoagulants, bleeding is the major adverse effect of nadroparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Arterial thrombosis, thromboembolism, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Calcinosis, hypoaldosteronism (causing hyperkalemia and/or hyponatremia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematological &amp; oncologic: Hemorrhage, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Hematoma at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Osteopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction (very rare), angioedema (very rare), eosinophilia (very rare), erythema, priapism (very rare), pruritus, skin necrosis (rare), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199011\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nadroparin, any component of the formulation, or to other low molecular weight heparins and/or heparin; acute infective endocarditis; active bleeding or increased risk of hemorrhage (hemostasis disorder); history of confirmed or suspected immunologically mediated heparin-induced thrombocytopenia (HIT) (delayed-onset severe thrombocytopenia) or positive in vitro test for antiplatelet antibodies in the presence of nadroparin; major blood clotting disorders; hemorrhagic tendency or other conditions involving increase risk of bleeding; organic lesions likely to bleed (active peptic ulceration); hemorrhagic cerebrovascular event; severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; injuries to or operations on the CNS, eyes, or ears; severe renal insufficiency (creatinine clearance &lt;30 mL/minute when used for treatment); concomitant use of spinal/epidural anesthesia with repeated high-dose nadroparin (eg, 171 units/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use of nadroparin in patients with current HIT or HIT with thrombosis is <b>not</b> recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (Guyatt [ACCP] 2012; Warkentin 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198994\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Bleeding may occur at any site during therapy. Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; hemorrhagic stroke; use shortly after brain, spinal, or ophthalmology surgery; in patients treated concomitantly with other drugs known to cause bleeding (eg, platelet inhibitors); recent GI bleeding or ulceration; vascular disorder of the chorio-retina; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; in patients undergoing invasive procedures; and in the elderly. Discontinue if bleeding occurs. Protamine infusion may be necessary for serious bleeding (consult Protamine monograph for dosing recommendations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous necrosis: Cutaneous necrosis preceded by purpura or infiltrated or painful erythematous blotches has been reported rarely; discontinue treatment immediately if suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia possibly by suppressing aldosterone production. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfunction, concomitant use of potassium-sparing diuretics or potassium supplements, hematoma in body tissues).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Cases of thrombocytopenia including thrombocytopenia with thrombosis have occurred. Use with caution in patients with history of thrombocytopenia (drug-induced or congenital) or platelet defects; monitor platelet count closely. Use is contraindicated in patients with a history of confirmed or suspected heparin-induced thrombocytopenia (HIT) or positive in vitro test for antiplatelet antibodies in the presence of nadroparin. Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm<sup>3</sup> and/or thrombosis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe arterial hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with history of GI ulceration; contraindicated in patients with active peptic ulceration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (has not been studied); patients with hepatic failure are at an increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prosthetic heart valves: Prosthetic valve thrombosis has been reported in patients receiving thromboprophylaxis therapy with LMWHs. Pregnant women may be at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; primarily renally excreted. Dose reductions may be required. Use is contraindicated in severe renal impairment when treating thromboembolic disorders, unstable angina, and NSTEMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; dosage reduction may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: There is no consensus for adjusting/correcting the weight-based dosage of LMWH for patients who are morbidly obese (BMI &ge;40 kg/m<sup>2</sup>). The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (Gould 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging (needle cover of prefilled syringe) may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do <b>not</b> administer intramuscularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other LMWHs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Knee surgery: Risk of bleeding may be increased in patients undergoing knee surgery and receiving LMWHs. Consider risk versus benefit in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuraxial anesthesia: Epidural or spinal hematomas, including subsequent long-term or permanent paralysis, may occur in patients anticoagulated with LMWH or heparinoids who are receiving neuraxial anesthesia (epidural or spinal anesthesia) or undergoing spinal puncture. Consider risk versus benefit prior to spinal procedures; risk is increased by concomitant agents which may alter hemostasis, the use of indwelling epidural catheters, a history of spinal deformity or spinal surgery, or a history of traumatic or repeated epidural or spinal punctures. Avoid lumbar puncture or spinal or epidural anesthesia for 12 hours following the last nadroparin prophylactic dose or 24 hours following the last nadroparin treatment dose. The timing of subsequent nadroparin doses following catheter removal should be based on careful risk assessment for thrombosis and bleeding. Longer intervals should be considered for patients with renal impairment (doubling the timing of catheter removal). Observe patient closely for bleeding and signs and symptoms of neurological impairment if therapy is administered. If spinal hematoma is suspected, diagnose and treat immediately; spinal cord decompression may be considered although it may not prevent or reverse neurological sequelae.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299734\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198998\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10060&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithrombin: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Canagliflozin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: Heparins (Low Molecular Weight) may increase the serum concentration of Palifermin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199014\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were not observed in animal reproduction studies. Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors (eg, homozygous factor V Leiden, antiphospholipid antibody syndrome with &ge;3 previous pregnancy losses). Prophylaxis is not routinely recommended for women undergoing assisted reproduction therapy; however, LMWH therapy is recommended for women who develop severe ovarian hyperstimulation syndrome. LMWH should be discontinued at least 24 hours prior to induction of labor or a planned cesarean delivery. For women undergoing cesarean section and who have additional risk factors for developing VTE, the prophylactic use of LMWH may be considered. For women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Bates 2012, Linnemann 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14081018\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of Low molecular weight heparins (LMWHs) may be present in breast milk; however, because they have a low oral bioavailability, LMWHs are unlikely to cause adverse events in a breastfeeding infant. Breastfeeding is not recommended by the manufacturer; however, antithrombotic guidelines note the use of LMWH may be continued in breastfeeding women (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199003\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Platelet counts (at baseline and then twice weekly during therapy), bleeding complications including stool occult blood tests, hemoglobin, antifactor Xa levels (recommended to obtain levels 4 hours postdose); renal and hepatic function; potassium in patients at risk for hyperkalemia; signs/symptoms of neurological impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When used for anticoagulation during hemodialysis, carefully monitor patients for signs of bleeding or clotting in the dialysis session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14081019\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Anti-Xa level target (measured 4 hours after administration): Treatment of venous thromboembolism (Garcia 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Once-daily dosing:</i> 1.3 Anti-Xa units/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Twice-daily dosing:</i> 0.6 to 1 Anti-Xa units/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198993\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nadroparin is a low molecular weight heparin (LMWH) (average molecular weight is ~4,300 daltons, distributed as 2,000 to 8,000 daltons [75% to 85%]) that binds antithrombin III, enhancing the inhibition of several clotting factors, particularly factor Xa. Nadroparin anti-Xa activity (85 to 110 units/mg) is greater than anti-IIa activity (~27 units/mg) and it has a higher ratio of antifactor Xa to antifactor IIa activity compared to unfractionated heparin. LMWHs have a small effect on the activated partial thromboplastin time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199010\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Note:</b> Values reflective of anti-Xa activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Anti-Xa activity: &ge;18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 3.59 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: ~98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~3.5 hours (prolonged in renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: SubQ: 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199015\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fraksyparyn (UA);</li>\n      <li>Fraxiparin (AT, DE, KW);</li>\n      <li>Fraxiparina (BR, ES, IT, PT, VE);</li>\n      <li>Fraxiparine (AE, AR, AU, BE, BG, BH, CH, CL, CN, CR, CU, CY, CZ, DO, EC, EE, EG, FI, FR, GR, GT, HK, HN, HR, HU, ID, IL, IN, JO, KR, LB, LT, LU, LV, MX, MY, NI, NL, NO, NZ, PA, PH, PK, PL, PY, QA, RO, RU, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN);</li>\n      <li>Fraxiparine Forte (PH, SG, TH);</li>\n      <li>Fraxiparine TX (CO, MX, PE, UY);</li>\n      <li>Fraxodi (BE, GR, JO, LU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26478547\"></a>Atiq F, van den Bemt LA, Leebeek FW, et al. No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency. <i>Neth J Med</i>. 2015;73(8):373-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/26478547/pubmed\" target=\"_blank\" id=\"26478547\">26478547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315276\"></a>Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e691S-e736S. doi: 10.1378/chest.11-2300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis R, Faulds D. Nadroparin Calcium. A Review of Its Pharmacology and Clinical Use in the Prevention and Treatment of Thromboembolic Disorders. <i>Drugs Aging. </i>1997;10(4):299-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/9108990/pubmed\" target=\"_blank\" id=\"9108990\">9108990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraxiparine and Fraxiparine Forte (nadroparin calcium). Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest. </i>2012;141(2):S227-S277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315263/pubmed\" target=\"_blank\" id=\"22315263\">22315263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linnemann B, Scholz U, Rott H, et al; Working Group in Women's Health of the Society of Thrombosis and Hemostasis. Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). <i>Vasa</i>. 2016;45(2):103-118. doi: 10.1024/0301-1526/a000504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/27058796/pubmed\" target=\"_blank\" id=\"27058796\">27058796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagge J, Crowther M, and Hirsh J. Is Impaired Renal Function a Contraindication to the Use of Low-Molecular Weight Heparin? <i>Arch Intern Med. </i>2002;162:2605-2609.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/12456233/pubmed\" target=\"_blank\" id=\"12456233\">12456233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings. <i>Ann Pharmacother.</i> 2009;43(6):1064-1083.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/19458109/pubmed\" target=\"_blank\" id=\"19458109\">19458109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10680037\"></a>Turpie AG. Can We Differentiate the Low-Molecular-Weight Heparins? <i>Clin Cardiol. </i>2000;23(suppl I):14-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/10680037/pubmed\" target=\"_blank\" id=\"10680037\">10680037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE and Barkin RL. Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy. </i>1999;19(2):181-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nadroparin-united-states-not-available-drug-information/abstract-text/10030768/pubmed\" target=\"_blank\" id=\"10030768\">10030768</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10060 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F199025\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F199059\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F199028\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062283\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F199029\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13219378\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F27749650\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10076317\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234097\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F199008\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F199007\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F199064\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F198996\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F199011\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F198994\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299734\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F198998\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F199014\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14081018\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F199003\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F14081019\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F198993\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F199010\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F199015\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10060|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nadroparin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Nadroparin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}